MedTrace Logo

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

NCT05726110 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-10-22

No results posted yet for this study

Summary

This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

Conditions

Interventions

DRUG

Selinexor

Given PO

DRUG

Homoharringtonine

Given per standard of care

DRUG

Daunorubicin

Given per standard of care

DRUG

Cytarabine

Given per standard of care

DRUG

Granulocyte Colony-Stimulating Factor

Given per standard of care

DRUG

Aclacinomycin

Given per standard of care

Sponsors & Collaborators

  • Antengene Corporation

    collaborator INDUSTRY

  • Shanxi Bethune Hospital

    lead OTHER

Principal Investigators

  • Tao Wang · Shanxi Bethune Hospital Regulatory Authority

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-29
Primary Completion
2024-12-10
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05726110 on ClinicalTrials.gov